Premium
Real‐life evaluation of a COVID‐19 rapid antigen detection test in hospitalized children
Author(s) -
Eleftheriou Irini,
Dasoula Foteini,
Dimopoulou Dimitra,
Lebessi Evangelia,
Serafi Eftihia,
Spyridis Nikos,
Tsolia Maria
Publication year - 2021
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.27149
Subject(s) - gold standard (test) , medicine , immunoassay , covid-19 , virology , epidemiology , serology , antigen , immunology , disease , infectious disease (medical specialty) , antibody
Rapid antigen detection (RAD) tests for the detection of SARS‐CoV‐2 are simpler, faster, and less expensive than the reverse‐transcription polymerase chain reaction (RT‐PCR) that is currently considered the gold standard for the diagnosis of coronavirus disease 2019 (COVID‐19). The objective of this study was to determine the performance of the PANBIO COVID‐19 Ag RAD (Abbott) test, a lateral flow immunoassay that detects the nucleocapsid protein, using as a reference RT‐PCR method the Cobas®8800 System (Roche Diagnostics). This prospective study was conducted in a tertiary Children's Hospital and included individuals aged ≤16 years with COVID‐19‐related symptoms or epidemiological criteria for COVID‐19. Two nasopharyngeal samples were collected to perform the PANBIO RAD test and RT‐PCR. Of 744 children included, 51 (6.86%) had a positive RT‐PCR result. The RAD test detected 42 of 51 PCR‐positive children while there were no false‐positive results. The overall sensitivity and specificity were 82.35% (95% CI, 71.9%–92.8%) and 100%, respectively. Sensitivity was >95% in symptomatic children. The assay performed poorly in asymptomatically infected children. In agreement with previous studies in adults, the PANBIO RAD test can be useful in screening for COVID‐19 in children admitted with symptoms suggestive of the disease, especially in the first days of the illness.